Lamivudine complexes with nucleic acids (green) in HBV
polymerase, highlighting residues related to drug resistance
Evivar and its consortium partners have built an extensive portfolio of patents & patent applications that relate to the identification of drug resistant HBV mutants.
The patents cover use of this HBV mutational data in diagnostic, therapeutic and clinical testings.
Evivar's patent portfolio also includes recent discoveries associated with multiple pathways of evolution of drug-resistance as well as cross-resistance and multi-drug resistance which can only be reliably identified by sequencing methodologies.
All material copyright Evivar Medical Pty. Ltd. All rights reserved